IL189246A0 - Albumin fusion proteins - Google Patents

Albumin fusion proteins

Info

Publication number
IL189246A0
IL189246A0 IL189246A IL18924608A IL189246A0 IL 189246 A0 IL189246 A0 IL 189246A0 IL 189246 A IL189246 A IL 189246A IL 18924608 A IL18924608 A IL 18924608A IL 189246 A0 IL189246 A0 IL 189246A0
Authority
IL
Israel
Prior art keywords
fusion proteins
albumin fusion
albumin
proteins
fusion
Prior art date
Application number
IL189246A
Other languages
English (en)
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of IL189246A0 publication Critical patent/IL189246A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL189246A 2005-08-12 2008-02-04 Albumin fusion proteins IL189246A0 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
IL189246A0 true IL189246A0 (en) 2008-08-07

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
IL189246A IL189246A0 (en) 2005-08-12 2008-02-04 Albumin fusion proteins

Country Status (13)

Country Link
EP (1) EP1924596A4 (enExample)
JP (1) JP2009504157A (enExample)
KR (1) KR20080071119A (enExample)
AU (1) AU2006280312A1 (enExample)
BR (1) BRPI0614761A2 (enExample)
CA (1) CA2618476A1 (enExample)
EC (1) ECSP088262A (enExample)
IL (1) IL189246A0 (enExample)
MA (1) MA29836B1 (enExample)
MX (1) MX2008001865A (enExample)
NO (1) NO20081233L (enExample)
TN (1) TNSN08064A1 (enExample)
WO (1) WO2007021494A2 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1278767A4 (en) 2000-04-12 2003-11-12 Principia Pharmaceutical Corp ALBUMIN FUSED PROTEINS
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
DK1729795T3 (en) 2004-02-09 2016-04-11 Human Genome Sciences Inc Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
BRPI0712383A2 (pt) 2006-06-07 2012-07-10 Human Genome Sciences Inc proteìnas de fusão da albumina
CA2663352A1 (en) * 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2896630B1 (en) 2007-01-30 2020-12-23 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
CA2749786A1 (en) 2009-01-16 2010-07-22 Jason Benjamin Bock New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
KR20100100254A (ko) * 2009-03-05 2010-09-15 (주)바이오큐어팜 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물
JP5813641B2 (ja) 2009-08-24 2015-11-17 アムニクス オペレーティング インコーポレイテッド 凝固第ix因子組成物ならびにそれを製造および使用する方法
EP3421491A3 (en) * 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
CA2800173C (en) * 2010-05-21 2019-05-14 Ulrik Nielsen Bi-specific fusion proteins
CN107261119A (zh) * 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
CN110272484A (zh) 2011-05-05 2019-09-24 阿尔布梅迪克斯医疗有限公司 白蛋白变体
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
DK2717898T3 (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
PL2804623T3 (pl) 2012-01-12 2020-03-31 Bioverativ Therapeutics Inc. Chimeryczne polipeptydy czynnika viii i ich zastosowania
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
SI2822577T1 (sl) 2012-02-15 2019-07-31 Bioverativ Therapeutics Inc. Rekombinantni proteini faktorja VIII
JP6441682B2 (ja) 2012-03-16 2018-12-19 アルブミディクス リミティド アルブミン変種
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CN103525695B (zh) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 便携式肾功能检测系统
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
PT3889173T (pt) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc Gene do fator viii otimizado
EP3318124A3 (en) 2013-02-16 2018-05-30 Albumedix A/S Pharmacokinetic animal model
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
SG11201509313PA (en) 2013-06-28 2016-01-28 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
ES2927475T3 (es) 2014-01-10 2022-11-07 Bioverativ Therapeutics Inc Proteínas quiméricas de factor VIII y usos de las mismas
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
CN108064282A (zh) 2014-10-14 2018-05-22 哈洛齐梅公司 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ix因子融合タンパク質及びそれらの製造方法及び使用方法
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
CN105254766B (zh) * 2015-10-26 2018-10-16 中国航天员科研训练中心 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
AU2017366709A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
JP2020517657A (ja) * 2017-04-20 2020-06-18 ノヴォ ノルディスク アー/エス アルブミン融合タンパク質の精製方法
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. NUCLEIC ACID MOLECULES AND USES THEREOF
JP2021512126A (ja) 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド 第viii因子を発現するレンチウイルスベクターの使用
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療a型血友病的方法
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
SG11202105880TA (en) 2018-12-06 2021-07-29 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor ix
CA3152600A1 (en) 2019-09-30 2021-04-08 Andrew KROETSCH Lentiviral vector formulations
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
JPWO2022030580A1 (enExample) * 2020-08-06 2022-02-10
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
EP4603587A1 (en) * 2022-10-11 2025-08-20 JCR Pharmaceuticals Co., Ltd. Fusion protein of serum albumin and physiologically-active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277889B1 (en) * 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
DK1729795T3 (en) * 2004-02-09 2016-04-11 Human Genome Sciences Inc Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
NO20081233L (no) 2008-05-09
KR20080071119A (ko) 2008-08-01
TNSN08064A1 (en) 2009-07-14
ECSP088262A (es) 2008-05-30
WO2007021494A2 (en) 2007-02-22
EP1924596A2 (en) 2008-05-28
MX2008001865A (es) 2008-04-15
EP1924596A4 (en) 2009-07-29
JP2009504157A (ja) 2009-02-05
AU2006280312A1 (en) 2007-02-22
BRPI0614761A2 (pt) 2009-05-19
MA29836B1 (fr) 2008-10-03
WO2007021494A3 (en) 2007-07-26
CA2618476A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
IL189246A0 (en) Albumin fusion proteins
IL176894A0 (en) Albumin fusion proteins
IL222924A0 (en) Albumin fusion proteins
IL197580A0 (en) Albumin fusion proteins
PL1830872T3 (pl) Białka fuzyjne
GB0426397D0 (en) Fusion proteins
IL204839A0 (en) Albumin fusion proteins
ZA200801224B (en) Albumin fusion proteins
EP1858546A4 (en) MODIFIED TRANSFERRINFUSION PROTEINS
EP1594530A4 (en) HYBRID PROTEINS OF ALBUMIN
IL196889A0 (en) Albumin-insulin fusion proteins
ZA200709871B (en) Interferon-IgG fusion
EP1934372A4 (en) SSB-POLYMERASE HYBRID PROTEINS
ZA200901280B (en) Exendin fusion proteins
GB0519965D0 (en) Joint fusion peg
GB0423974D0 (en) Proteins
PL1879909T3 (pl) Roztwór albuminy pozbawiony cząsteczek stabilizatora
HK1113581A (en) Albumin fusion proteins
GB0426399D0 (en) Fusion proteins
HK1131548A (en) Albumin fusion proteins
AU2005905300A0 (en) Fusion Protein
GB0511861D0 (en) Proteins
GB0423002D0 (en) Proteins
GB0513505D0 (en) Proteins
GB0514788D0 (en) Proteins